Biovance Capital Partners
Also known as Biovance Capital, Biovance Capital Partners, Sociedade de Capital de Risco, S.A.
Lisbon biotech VC managing Biovance Capital Fund I (€57M as of Jun 2025, €60M max); seed and Series A tickets of €1.5M–€6M in European drug-development companies.
- HEADQUARTERS
- Lisbon, Portugal
- FOUNDED
- —
- AUM
- €57M (2025)
- OUTSIDE CAPITAL
- Yes
- TEAM LISTED
- 10 people
Focus
- STAGES
- SeedSeries A
- SECTORS
- Biotech & Life Sciences
- ASSET MIX
- Venture capitalDirect investments
- GEOGRAPHY
- Europe
Overview
Biovance Capital Partners, Sociedade de Capital de Risco, S.A. is a Lisbon-based venture capital firm (with a second office in Matosinhos, Porto) that manages Biovance Capital Fund I, which held a €51M first close in 2024 and reached €57M in June 2025 against a €60M maximum. Fund investors include the European Investment Fund, Banco Português de Fomento, the European Commission (Portugal Tech and InvestEU), BIAL, Caixa Capital, Ageas Pensões, Fundo de Pensões EDP and private investors from Portugal, the US and Europe. The fund invests €1.5M–€6M in seed and Series A rounds of drug-development companies across Europe, with a focus on Southern Europe, in any modality or therapeutic area. By September 2026 it had made three investments: Mondego Bio (2025), Laigo Bio (2026) and Vaxdyn (2026).
Investment thesis
Seed and Series A investments in European therapeutics companies of any modality and therapeutic area, with a Southern Europe focus; requires robust preclinical models and patented or patentable assets, large markets with a clear regulatory pathway, and sectors with M&A or IPO exit activity.
PORTFOLIO (3)
- Mondego BioNOTABLEBiotech & Life Sciences · since 2025
- Laigo BioNOTABLEBiotech & Life Sciences · since 2026
- VaxdynNOTABLEBiotech & Life Sciences · since 2026
People
Links
Frequently asked questions
Biovance Capital Partners is a VC fund based in Lisbon, Portugal.
Yes. Biovance Capital Partners invests its own capital in private companies.
Biovance Capital Partners invests at Seed and Series A stages in Biotech & Life Sciences.
Biovance Capital Partners's stated ticket size is €1.5M–€6M.
Key people at Biovance Capital Partners include Ricardo Perdigão Henriques (Managing Partner), João Incio (General Partner), André Albergaria (Principal) and Peter Villax (Non-Executive Partner).
Biovance Capital Partners's investments include Mondego Bio, Laigo Bio and Vaxdyn.
The most recent publicly reported investment by Biovance Capital Partners is Vaxdyn (Series A (€11M round, lead; €4M from Biovance)), announced in Sep 2026.
Biovance Capital Partners states that it accepts submissions through its official contact page.
Yes. Biovance Capital Partners manages capital from outside investors.